We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Better Biosensors Made with Electron Density Waves

By LabMedica International staff writers
Posted on 18 Nov 2010
An emerging field called optofluidic plasmonics has the potential for a new way to detect and analyze biologic molecules for drug discovery, medical diagnostics, and the detection of biochemical weapons. More...


Investigators from the University of California, San Diego (UCSD; USA) led by Dr. Yeshaiahu Fainman have succeeded in merging a microfluidics system with plasmonics--also called "light on a wire”--onto a single platform. Plasmonics is based on electron waves on a metal surface excited by incoming light waves.

According to Dr. Fainman, tapping the potential of plasmonics for biomolecule detection systems has been a challenge, because localized optical field scales are usually much larger than the molecules being studied. In order to make a useful optical biosensor, he stated, "We need to increase the interaction cross-section by finding ways to localize optical interrogation fields ideally to the scales comparable to those of biomolecules.”

Since that is not currently possible, he and his team used an approach of integrating microfluidics and plasmonics on single chips, allowing fluid to transport the molecules into the cross-section of the optical field. Dr. Fainman expects the system to be especially beneficial in examining large arrays of protein-protein interactions for identifying potential drugs that bind to specific target molecules, which may lead to earlier cancer diagnoses and faster discovery of new drugs. Unlike most traditional techniques, optical detection does not require labeling of molecules with fluorescent or radioactive entities--labels frequently suppress interaction by covering up or blocking binding surfaces.

The new platform also carries the advantage of being high throughput and multiplexed, offering researchers an opportunity to examine thousands of arrayed compounds simultaneously, which Dr. Fainman concluded, "Biologists and physicians get very excited about.”

The study's findings were presentation, presented October 26, 2010, at the Frontiers in Optics (FiO) 2010/Laser Science XXVI--the 94th annual meeting of the Optical Society (OSA), which was held together with the annual meeting of the American Physical Society (APS) Division of Laser Science in Rochester, NY, USA, from October 24-28.

Related Links:
University of California, San Diego


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.